- Home
- ALXO vs BEAT Comparison
ALXO vs BEAT Comparison
Compare ALXO & BEAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALXO
- BEAT
- Stock Information
- Founded
- ALXO 2015
- BEAT 2015
- Country
- ALXO United States
- BEAT United States
- Employees
- ALXO N/A
- BEAT N/A
- Industry
- ALXO Biotechnology: Pharmaceutical Preparations
- BEAT Retail: Computer Software & Peripheral Equipment
- Sector
- ALXO Health Care
- BEAT Technology
- Exchange
- ALXO Nasdaq
- BEAT Nasdaq
- Market Cap
- ALXO 76.5M
- BEAT 65.1M
- IPO Year
- ALXO 2020
- BEAT 2021
- Fundamental
- Price
- ALXO $1.12
- BEAT $2.08
- Analyst Decision
- ALXO Buy
- BEAT Buy
- Analyst Count
- ALXO 6
- BEAT 1
- Target Price
- ALXO $6.64
- BEAT $8.00
- AVG Volume (30 Days)
- ALXO 769.2K
- BEAT 131.3K
- Earning Date
- ALXO 03-06-2025
- BEAT 03-19-2025
- Dividend Yield
- ALXO N/A
- BEAT N/A
- EPS Growth
- ALXO N/A
- BEAT N/A
- EPS
- ALXO N/A
- BEAT N/A
- Revenue
- ALXO N/A
- BEAT N/A
- Revenue This Year
- ALXO N/A
- BEAT N/A
- Revenue Next Year
- ALXO N/A
- BEAT N/A
- P/E Ratio
- ALXO N/A
- BEAT N/A
- Revenue Growth
- ALXO N/A
- BEAT N/A
- 52 Week Low
- ALXO $0.96
- BEAT $1.35
- 52 Week High
- ALXO $17.83
- BEAT $3.48
- Technical
- Relative Strength Index (RSI)
- ALXO 38.53
- BEAT 39.34
- Support Level
- ALXO $1.00
- BEAT $2.05
- Resistance Level
- ALXO $1.22
- BEAT $2.37
- Average True Range (ATR)
- ALXO 0.09
- BEAT 0.18
- MACD
- ALXO 0.00
- BEAT -0.02
- Stochastic Oscillator
- ALXO 35.12
- BEAT 21.24
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
About BEAT Heartbeam Inc.
HeartBeam Inc is a medical technology company primarily focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.